SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD)

Eur Neuropsychopharmacol. 2005 Oct;15(5):521-4. doi: 10.1016/j.euroneuro.2005.01.003.

Abstract

Serotonin and dopamine transporter (SERT, DAT) availabilities have prospectively been investigated using [123I]beta-CIT and single photon emission computed tomography in subjects with obsessive-compulsive disorder under treatment with the selective serotonin reuptake inhibitor citalopram. SERT availability decreased by a mean 36.5%, whereas DAT availability increased by about 40%. The data point at a citalopram induced modulation of both serotonergic and dopaminergic activity and support the notion of functional interactions of monoaminergic systems in the human brain.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain / diagnostic imaging
  • Brain / drug effects
  • Brain / metabolism*
  • Citalopram / pharmacokinetics
  • Citalopram / pharmacology*
  • Humans
  • Obsessive-Compulsive Disorder / drug therapy
  • Obsessive-Compulsive Disorder / metabolism*
  • Selective Serotonin Reuptake Inhibitors / pharmacokinetics
  • Selective Serotonin Reuptake Inhibitors / pharmacology
  • Tomography, Emission-Computed, Single-Photon

Substances

  • Serotonin Uptake Inhibitors
  • Citalopram